Skip to main content
    H

    Halozyme Therapeutics Inc (HALO)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $96.50
    -3.77 (-3.76%)

    Market Cap: $11.43B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Halozyme Therapeutics Inc (HALO) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Halozyme Therapeutics are Exelixis (EXEL), Summit Therapeutics (SMMT) and BridgeBio Pharma (BBIO). Halozyme Therapeutics trades at 17.8x earnings, against a median of 39.6x for the 7 of these companies with a P/E. By market cap, Halozyme Therapeutics ranks 5th of the 13 companies on this page; Exelixis (EXEL) is the largest at $16.84B.

    Peer Comparison

    HALO's ROIC of 15.8% is above the peer median of 1.8%, and its revenue growth of 39.2% is above the median of 20.3%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Halozyme Therapeutics (HALO)$11.43B17.8x6.1x26.9%15.8%39.2%0.00%
    Exelixis Inc (EXEL)$16.84B19.3x6.9x35.4%N/A10.2%0.00%
    Summit Therapeutics PLC (SMMT)$11.32BN/AN/A0.0%N/A-100.0%0.00%
    BridgeBio Pharma Inc (BBIO)$15.25BN/A16.0x-59.8%-33.0%192.6%0.00%
    TG Therapeutics Inc (TGTX)$9.75B87.2x11.1x11.8%11.0%60.7%0.00%
    Apogee Therapeutics, Inc. Common Stock (APGE)$10.22BN/AN/A0.0%N/A0.0%0.00%
    Jazz Pharmaceuticals PLC (JAZZ)$15.50B18.4x3.3x4.4%3.5%10.4%0.00%
    Kymera Therapeutics Inc (KYMR)$10.89BN/A123.2x0.0%N/A466.4%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Bio-Techne Corp (TECH)$11.44B39.6x9.3x14.0%7.7%4.6%0.44%
    Ligand Pharmaceuticals Incorporated (LGND)$6.18B66.5x23.7x20.3%0.1%-31.8%0.00%
    Krystal Biotech Inc (KRYS)$9.05B40.4x18.8x47.9%N/A30.2%0.00%
    Axsome Therapeutics Inc (AXSM)$7.45BN/A8.6x-18.2%-48.1%51.9%0.00%
    Peer median$10.56B39.6x13.4x8.1%1.8%20.3%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Halozyme Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Exelixis Inc (EXEL)
    Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development...
    EXEL competitors
    Summit Therapeutics PLC (SMMT)
    Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America...
    SMMT competitors
    BridgeBio Pharma Inc (BBIO)
    BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases.
    BBIO competitors
    TG Therapeutics Inc (TGTX)
    TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development...
    TGTX competitors
    Apogee Therapeutics, Inc. Common Stock (APGE)
    Apogee Therapeutics, Inc., through its subsidiary, is a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD)...
    Jazz Pharmaceuticals PLC (JAZZ)
    Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and markets pharmaceutical products for various unmet medical needs in the United...
    JAZZ competitors
    Kymera Therapeutics Inc (KYMR)
    Kymera Therapeutics, Inc., a biopharmaceutical company, is focused on discovering and developing new small molecule treatments that selectively break down...
    KYMR competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors
    Bio-Techne Corp (TECH)
    Bio-Techne Corporation develops, manufactures, and sells life science reagents, instruments...
    TECH competitors
    Ligand Pharmaceuticals Incorporated (LGND)
    Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover...
    LGND competitors
    Krystal Biotech Inc (KRYS)
    Krystal Biotech, Inc., a clinical-stage biotechnology company, is dedicated to the field of redosable gene therapy to treat serious rare diseases in the United...
    KRYS competitors
    Axsome Therapeutics Inc (AXSM)
    Axsome Therapeutics, Inc., a biopharmaceutical company, is dedicated to developing new therapies for central nervous system (CNS) disorders in the United...
    AXSM competitors

    Frequently Asked Questions About HALO

    Who are Halozyme Therapeutics' main competitors?

    The companies most similar to Halozyme Therapeutics include Exelixis (EXEL), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), TG Therapeutics (TGTX) and Apogee Therapeutics, Inc. Common Stock (APGE), listed from the closest match.

    Who is Halozyme Therapeutics' biggest competitor?

    Exelixis (EXEL) is both the largest of the similar companies at $16.84B and the closest match by business profile, size, sector and industry.

    How does HALO stock compare with its competitors?

    HALO's P/E is 17.8x against a peer median of 39.6x; its P/S is 6.1x against a peer median of 13.4x; its net margin is 26.9% against a peer median of 8.1%.

    Which of Halozyme Therapeutics' competitors pays a higher dividend?

    Halozyme Therapeutics pays no dividend. Bio-Techne (TECH) has a higher forward dividend yield; Bio-Techne (TECH) has the highest at 0.44%.

    Is Halozyme Therapeutics bigger than its competitors?

    No. Halozyme Therapeutics is 5th by market cap among the 13 companies on this page; the largest is Exelixis (EXEL) at $16.84B.